A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care for Subjects With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Whose Disease Has Progressed Despite Prior Treatment With at Least Imatinib and Sunitinib

Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care for Subjects With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Whose Disease Has Progressed Despite Prior Treatment With at Least Imatinib and Sunitinib

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms GRID
  • Sponsors Bayer
  • Most Recent Events

    • 15 Nov 2017 Planned End Date changed from 31 Dec 2017 to 31 Dec 2018.
    • 12 Sep 2017 Results of exploratory analysis assessing relationship between tumor growth rate and progression-free survival and overall survival for patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) receiving placebo or regorafenib, were presented at the 42nd European Society for Medical Oncology Congress.
    • 01 Sep 2017 According to a Bayer media release, data regarding tumor growth rate analysis will be presented at the European Society for Medical Oncology (ESMO) Congress in Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top